The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

@article{Mohler2008TheEO,
  title={The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.},
  author={E. Mohler and C. Ballantyne and M. Davidson and M. Hanefeld and L. Ruilope and Joel P. L. Johnson and A. Zalewski},
  journal={Journal of the American College of Cardiology},
  year={2008},
  volume={51 17},
  pages={
          1632-41
        }
}
OBJECTIVES This study examined the effects of darapladib, a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk. BACKGROUND Elevated Lp-PLA(2) levels are associated with an increased risk of CV events. METHODS Coronary heart disease (CHD) and CHD-risk equivalent patients (n = 959) receiving atorvastatin (20 or 80 mg) were randomized to oral darapladib 40 mg, 80 mg, 160 mg, or placebo once daily for 12 weeks. Blood samples were… Expand
217 Citations
Peripheral artery disease, biomarkers, and darapladib.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 52 REFERENCES
Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2
...
1
2
3
4
5
...